Senior Editor, OncLive®
Jason Harris has worked in journalism for more than 20 years, including stints at daily newspapers and niche publications for oncology and cardiology. He is a senior editor for OncologyLive® and managing editor for Oncology Fellows and the annual Giants of Cancer Care® album. He also contributes to the OncLive On Air and OncFellows podcasts. Email: jharris@onclive.com
European Commission Recommends Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer
December 19th 2022The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval for the use of trastuzumab deruxtecan monotherapy for adults with unresectable or metastatic HER2-low breast cancer.
Read More
FDA Delays PDUFA Hearing for Olaparib/Abiraterone Combo in mCRPC
December 15th 2022The FDA has told AstraZeneca and MSD that the agency will extend the Prescription Drug User Fee Act date by 3 months to provide further time for a full review of the supplementary new drug application for olaparib plus abiraterone and prednisone or prednisolone for patients with mCRPC.
Read More
ASTRO Provides New Guidelines for Use of Radiation and Systemic Therapies in Endometrial Cancer
December 8th 2022ASTRO has updated guidance for the use of radiation therapy and systemic therapy for patients who’ve undergone surgery for endometrial cancer. The guideline also considers the role of surgical staging and molecular profiling techniques in determining whether a patient should receive post-operative therapy.
Read More
Pembrolizumab Appears Safe Across Melanoma, NSCLC, RCC in Pooled Analysis
December 8th 2022Pembrolizumab induced treatment-related adverse effects that were generally mild or moderate in severity, according to finding from a pooled analysis of more than 4000 patients with melanoma, non–small cell lung cancer, or renal cell carcinoma.
Read More
EMA Accepts Marketing Authorization Application for Aumolertinib in EGFR-Mutated NSCLC
December 2nd 2022Pharmaceutical manufacturer EQRx announced December 2, 2022, that the European Medicines Agency has accepted a marketing authorization application for the use of aumolertinib in EGFR-mutated non–small cell lung cancer and locally advanced or metastatic EGFR T790M mutation–positive NSCLC.
Read More
Luminary Awards Honor GI Experts, Patient Advocate
November 18th 2022OncLive® and The Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center, have recognized 4 gastrointestinal physician-scientists and a prominent patient advocate, naming them as 2022 Luminary Awards in GI Cancers.
Read More
NICE Recommends Mobocertinib for Rare, Aggressive Lung Cancer
November 16th 2022The United Kingdom’s National Institute for Health and Care Excellence has issued final guidance recommending the use of mobocertinib for patients with advanced non–small cell lung cancer harboring EGFR exon 20 insertion mutations who have already received platinum-based chemotherapy.
Read More
Osimertinib Remains the Preferred Frontline Choice for EGFR-Mutated NSCLC
November 14th 2022Osimertinib remains the preferred first-line therapy for patients with EGFR-mutated non–small cell lung cancer. However, for those with classic EGFR mutations, the day is fast approaching when physicians will add chemotherapy to first-line treatment with the EGFR TKI based on ctDNA results.
Read More
NICE Recommends Neoadjuvant Pembrolizumab/Chemotherapy, Followed by Adjuvant Pembrolizumab for TNBC
November 8th 2022The National Institute for Health and Care Excellence has issued final guidance supporting use of neoadjuvant pembrolizumab in combination with chemotherapy, followed by adjuvant pembrolizumab, for adults with triple-negative breast cancer.
Read More
Fulvestrant/Palbociclib Doubles PFS in ESR1+ Advanced Breast Cancer
November 7th 2022Fulvestrant plus palbociclib improved outcomes following an aromatase inhibitor plus palbociclib for patients with estrogen receptor–positive, HER2-negative advanced breast cancer with rising ESR1 mutation, according to updated findings from the phase 3 PADA-1 trial.
Read More
Ibrutinib Demonstrates Long-Term Efficacy in CLL in Real-World Setting
November 3rd 2022Ibrutinib induced a cumulative overall response rate of 90.0% in 3-year findings from the Belgian Ibrutinib Real‑World Data study of patients with previously untreated or relapsed/refractory chronic lymphocytic leukemia.
Read More
Lorlatinib Improves PFS, Reduces CNS Progression in Advanced ALK+ NSCLC
November 2nd 2022Lorlatinib improved progression-free survival and reduced 12-month cumulative incidence of central nervous system progression compared with crizotinib in patients with advanced ALK-positive non–small cell lung cancer irrespective of brain metastases at baseline.
Read More
Telisotuzumab Vedotin Plus Erlotinib Shows Encouraging Activity in Advanced c-Met+ NSCLC
November 1st 2022Telisotuzumab vedotin in combination with erlotinib induced promising outcomes in patients with advanced, EGFR-mutated, c-MET-positive non–small cell lung cancer who were contraindicated for surgery or other approved therapies.
Read More
Antidrug Antibodies Against Atezolizumab Associated With Poor Outcomes in HCC
October 27th 2022Highly elevated levels of antidrug antibodies against atezolizumab were associated with poorer clinical outcomes for patients who received atezolizumab plus bevacizumab for advanced hepatocellular carcinoma.
Read More
Mitomycin C Reduces the Number of Procedures Following NMIBC Recurrence
October 21st 2022Chemoresection with mitomycin C, a nonsurgical treatment modality, significantly reduced the need for transurethral resection of bladder tumors or office biopsy and tumor fulguration following recurrence in patients with recurrent nonmuscle invasive bladder cancer.
Read More